Last close As at 05/08/2026
EUR23.40
▲ 0.60 (2.63%)
Market capitalisation
EUR317m
Research: Financials
JDC Group’s (JDC) efforts to develop its digital platform to provide administrative and sales support and to stimulate its clients’ bancassurance business have started to drive earnings. As new contracts are onboarded, JDC should further strengthen its market position and also leverage the broader trend where traditional financial institutions enter into partnerships with fintechs. Prudent cost management and the ability to efficiently scale up the platform are key aspects to track going forward.
JDC Group |
Large contracts start to materialise
Diversified financials |
Scale research report - Update
4 September 2019 |
Share price graph
Share details
Business description
Bull
Bear
Analyst
|
||||||||||||||||||||||||||
JDC Group’s (JDC) efforts to develop its digital platform to provide administrative and sales support and to stimulate its clients’ bancassurance business have started to drive earnings. As new contracts are onboarded, JDC should further strengthen its market position and also leverage the broader trend where traditional financial institutions enter into partnerships with fintechs. Prudent cost management and the ability to efficiently scale up the platform are key aspects to track going forward.
Albatros contract now fully on stream
JDC reported 18% y-o-y EBITDA growth in H119 to €2.4m on the back of a full earnings contribution from the Albatros outsourcing contract in the Advisortech segment. The new outsourcing agreement has offset additional personnel and IT expenses due to further expansion of JDC’s platform. Meanwhile, its traditional Advisory segment (which now represents only 15% of group sales) reported zero EBITDA (vs a marginal loss of €0.1m in H118). JDC’s cash position was €5.5m at end-June 2019 vs €11.8m at end-2018 mostly due to cash paid for the broker pool KOMM and a reduction in the accounts payable balance.
Time to benefit from scaling the platform
JDC’s H119 revenues were €52.5m (up 18% y-o-y). Management confirmed its earlier FY19 guidance and still expects revenues of at least €110m (and c 15% y-o-y growth), as well as significantly higher EBITDA. Prospective earnings growth is underpinned by the ramp up in the cooperation with recently won clients (Albatros, Sparda, comdirect, Rheinland Versicherungs and Bavaria Wirtschaftsagentur) and full consolidation of KOMM’s results. This may be further strengthened if JDC is able to efficiently manage its expenses related to the digital platform. Further upside comes from potential new contract wins, with a high degree of confidence presented by JDC’s management with this respect.
Valuation: Reflecting early days of profitability
Given that JDC is on the eve of breaking even at the net income level, it continues to trade at a sizeable premium to the peer group based on its consensus FY19e P/E of 56.3x (vs the peer average of 16.6x). The ratio declines to 20.7x in FY20e, reflecting solid earnings growth expectations implied by the current consensus. This still translates into a c 43% premium to the peer group in FY20e, which may be warranted if JDC continues to scale up its technological platform.
|
Consensus estimates
Source: JDC Group, Refinitiv consensus at 29 August 2019 |
Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts.
H119 results: EBITDA up despite further investments
JDC Group reported a healthy 18% y-o-y increase in EBITDA to €2.4m, despite the additional personnel and IT costs incurred in preparation for the onboarding of large contracts (comdirect and Sparda in particular). This increase was mainly driven by the Advisortech segment which reported EBITDA of €3.1m (vs €2.6m in H118) while the EBITDA margin was c 7.0% (broadly comparable with the 7.1% in H118). We understand that this was largely due to the realisation of the Albatros contract which has been fully onboarded. The contracts with comdirect, Sparda Versicherungsservice and Bavaria Wirtschaftsagentur have not contributed to the H119 results yet. EBITDA in the traditional direct-to-customer business (the Advisory segment) was zero in H119 (vs a slight €0.1m loss in H118).
JDC’s sales were up by 18% y-o-y as well, generating €52.5m in H119, with Q219 revenues increasing by 17% y-o-y to €25.7m (only slightly below Q119 despite the second quarter normally being a low season). Advisortech sales were up c 22% y-o-y to €44.4m (and thus made up 85% of the group’s top line) while the Advisory segment posted a 6.2% y-o-y increase in sales to €12.9m in H119.
Initial commission at group level increased by 23.2% y-o-y to €34.2m, with similar growth rates in insurance products, investment funds and shares/closed-end funds. Commission income on investment products went up mostly in Q219, which we understand is in part associated with the first-time consolidation of the broker pool KOMM (acquired in April 2019). The ratio of commission expenses to JDC’s total revenue, which illustrates the proportion of commission fees paid out to affiliated brokers, increased slightly to 71% in H119 versus 69% in H118. JDC receives a commission on products sold through its platform and rebates the majority of it to the affiliated intermediary that conducted the sale.
In conjunction with the further development of the digital platform, JDC expanded its team – the average headcount on an annual basis was 280 versus 255 a year ago – resulting in a 9.6% y-o-y rise in personnel expenses to €8.4m. This was accompanied by higher IT costs of €1.6m (vs €1.4m in H118). Consequently, JDC’s net income was a minor positive €145k (vs a €210k loss in H118).
Exhibit 1: H119 results highlights
€’000s unless otherwise stated |
H119 |
H118 |
change y-o-y |
Total revenue |
52,513 |
44,474 |
18% |
Initial commission |
34,204 |
27,757 |
23% |
Insurance products |
25,140 |
20,219 |
24% |
Investment funds |
6,838 |
5,763 |
19% |
Shares/Closed-end funds |
2,226 |
1,775 |
25% |
Follow-up commission |
9,284 |
8,898 |
4% |
Overrides |
3,562 |
3,665 |
-3% |
Services |
1,666 |
1,076 |
55% |
Fee-based advisory |
1,490 |
1,546 |
-4% |
Other income |
2,307 |
1,532 |
51% |
Capitalised services |
488 |
338 |
44% |
Other operating income |
99 |
169 |
-41% |
Commission expenses |
(37,506) |
(30,630) |
22% |
Commission expense as % of revenues |
71% |
69% |
255bp |
Personnel expenses |
(8,369) |
(7,633) |
10% |
Other operating expenses |
(4,858) |
(4,704) |
3% |
EBITDA |
2,367 |
2,014 |
18% |
D&A |
(1,586) |
(1,361) |
17% |
EBIT |
781 |
653 |
20% |
PBT |
206 |
70 |
194% |
Net income |
145 |
(210) |
N/M |
EPS (€) |
0.01 |
(0.02) |
N/M |
Source: JDC Group, Edison Investment Research
JDC’s equity ratio was 40.1% at end-June 2019, up slightly from 39.0% at end-2018. That said, its net debt to equity ratio rose from 18% to 36% due to a reduced cash position which at end-June 2019 was €5.5m (vs €11.8m at end-2018). This was largely consumed by the €3.6m paid for the acquisition of the broker pool KOMM Investment & Anlagevermittlungs (as discussed in our previous update note). This has been the only transaction so far this year as part of JDC’s market consolidation efforts. Other major cash outflows in the period included accounts payable repayments as well as further investments in JDC’s digital platform, although the latter was less extensive than in H118 (with cash investments in intangible assets at €1.3m vs €3.9m).
Prospective growth secured by outsourcing contracts
The company reaffirmed its FY19 guidance of sales of at least €110m (implying a growth rate of c 15% y-o-y) and significantly higher EBITDA (the reported figure for FY18 was €1.5m in FY18) despite experiencing some headwinds from the overall economic slowdown which is limiting customer spending on investment and life insurance products. Inflows to German investment funds were up slightly in H119 to €41.9bn from €40.6bn in H118 (according to the German Investment Funds Association), driven predominantly by open-ended special funds. At the same time, retail funds attracted a modest €1.8bn of net inflows in H119 vs c €11.4bn in H118. Gross premiums in the German insurance sector rose by c 2% y-o-y in 2018, with similar growth expected for 2019 by the German Insurance Association (GDV).
JDC’s focus going forward will be on signing up new customers, as well as the optimisation of internal processes and cost management, which should translate into improved profitability. Management’s half year report suggests that the company is likely to announce new outsourcing contracts for its Advisortech business in the second half of the year. Results in H219 and FY20 should be assisted by the contracts with Sparda Versicherungsservice, RheinLand Versicherungs and comdirect. Moreover, we note that following the successful completion of a pilot project, JDC Group has agreed on a long-term outsourcing cooperation in August 2019 with Bavaria Wirtschaftsagentur (a subsidiary of BMW). The contract covers the provision of the administrative and sales support platform and takeover of associated processes. Going forward, JDC’s goal is to be an outsourcing partner of choice for handling retail client insurance products on behalf of large and very large financial intermediaries in Central Europe.
Valuation
From a limited number of close domestic peers, we have selected several companies that may be helpful in setting a context for JDC’s valuation, although we note that most address somewhat different markets and have different business models. In the independent financial advisors (IFAs) peer group we have included MLP as a direct competitor named by JDC’s management. JDC continues to trade at a considerable premium on the basis of FY19e P/E (due to marginal earnings expected this year), declining to c 43% in FY20e, which may reflect market expectations of the ramp up in cooperation with major new clients.
From a valuation perspective, it is instructive to examine the recent change in shareholder structure. In March 2019, JDC announced that Great-West Lifeco Group, a leading financial service provider based in Canada, will become JDC’s largest shareholder after acquiring a 28% stake through several purchase agreements with the family offices of JDC’s founders, Ralph Konrad and Sebastian Grabmaier. As a result, the founders will hold a c 10% stake in the company and intend to remain on board in the long term. It is important to note, that (as highlighted by the company in its FY18 report) the stake is being acquired at a valuation that is ‘significantly above the current market value of JDC Group’.
We also note that JDC launched a share buyback programme in July this year covering up to 5% of the company’s share capital. It intends to spend up to €5m between August 2019 and July 2020 on share repurchase.
Exhibit 2: Peer comparison table
Currency |
Market cap |
P/E (x) |
||
(m) |
2019e |
2020e |
||
Fintech |
EUR |
522 |
24.6 |
19.0 |
Avanza |
SEK |
11,946 |
27.6 |
23.2 |
Swissquote |
CHF |
622 |
14.8 |
12.3 |
BinckBank |
EUR |
428 |
20.5 |
18.4 |
Interactive brokers |
USD |
18,886 |
20.1 |
18.5 |
Average online brokers |
- |
|
21.5 |
18.3 |
AFH Financial Group |
GBP |
126 |
9.6 |
8.2 |
MLP |
EUR |
491 |
13.9 |
13.1 |
Average IFAs |
- |
|
11.8 |
10.7 |
Overall peer group average |
- |
|
16.6 |
14.5 |
JDC Group AG |
EUR |
71 |
56.3 |
20.7 |
Premium/(discount) to peer group |
- |
238% |
43% |
|
Source: Company data, Refinitiv consensus at 29 August 2019
|
|||||||||||
Research: Healthcare
Two ONCOS-102 readouts are expected in the next 12 months: mesothelioma Phase I/II data around new year 2020, and data from the Phase I melanoma study in H120. Targovax is also conducting preclinical trials with its new oncolytic viruses, with first results likely to be released in H219. This will support its move to becoming a focused oncolytic virus company. In addition, it provided an update on the Phase I/II trial with ONCOS-102 + Imfinzi (durvalumab) in patients with advanced peritoneal malignancies in collaboration with the Ludwig Institute for Cancer Research, where the expansion part has now started. Our Targovax valuation is virtually unchanged at NOK1.18bn or NOK18.6/share (vs NOK18.9/share previously).